PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis
ZUG, Switzerland--(Business Wire/Korea Newswire)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality ...
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


